Literature DB >> 34741185

Role for animal models in understanding essential fatty acid deficiency in cystic fibrosis.

Deanne H Hryciw1,2,3, Courtney A Jackson4, Nirajan Shrestha5, David Parsons6,7,8, Martin Donnelley6,7,8, Andrew J McAinch9,10.   

Abstract

Essential fatty acid deficiency has been observed in most patients with Cystic Fibrosis (CF); however, pancreatic supplementation does not restore the deficiency, suggesting a different pathology independent of the pancreas. At this time, the underlying pathological mechanisms are largely unknown. Essential fatty acids are obtained from the diet and processed by organs including the liver and intestine, two organs significantly impacted by mutations in the cystic fibrosis transmembrane conductance regulator gene (Cftr). There are several CF animal models in a variety of species that have been developed to investigate molecular mechanisms associated with the CF phenotype. Specifically, global and systemic mutations in Cftr which mimic genotypic changes identified in CF patients have been generated in mice, rats, sheep, pigs and ferrets. These mutations produce CFTR proteins with a gating defect, trafficking defect, or an absent or inactive CFTR channel. Essential fatty acids are critical to CFTR function, with a bidirectional relationship between CFTR and essential fatty acids proposed. Currently, there are limited analyses on the essential fatty acid status in most of these animal models. Of interest, in the mouse model, essential fatty acid status is dependent on the genotype and resultant phenotype of the mouse. Future investigations should identify an optimal animal model that has most of the phenotypic changes associated with CF including the essential fatty acid deficiencies, which can be used in the development of therapeutics.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Animal models; Arachidonic acid; Cftr; Cystic fibrosis; Docosahexaenoic acid; Essential fatty acid; Linoleic acid

Mesh:

Substances:

Year:  2021        PMID: 34741185     DOI: 10.1007/s00018-021-04014-2

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  57 in total

1.  Lower airway inflammation in infants with cystic fibrosis detected by newborn screening.

Authors:  David S Armstrong; Sarah M Hook; Kris M Jamsen; Gillian M Nixon; Rosemary Carzino; John B Carlin; Colin F Robertson; Keith Grimwood
Journal:  Pediatr Pulmonol       Date:  2005-12

2.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

Review 3.  The impact of newborn screening and earlier intervention on the clinical course of cystic fibrosis.

Authors:  F Nicole Dijk; Dominic A Fitzgerald
Journal:  Paediatr Respir Rev       Date:  2012-07-10       Impact factor: 2.726

4.  Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain fatty acids.

Authors:  M Kalivianakis; D M Minich; C M Bijleveld; W M van Aalderen; F Stellaard; M Laseur; R J Vonk; H J Verkade
Journal:  Am J Clin Nutr       Date:  1999-01       Impact factor: 7.045

5.  Fatty acid abnormalities in cystic fibrosis.

Authors:  P M Farrell; E H Mischler; M J Engle; D J Brown; S M Lau
Journal:  Pediatr Res       Date:  1985-01       Impact factor: 3.756

Review 6.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

7.  Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.

Authors:  Valeria Capurro; Valeria Tomati; Elvira Sondo; Mario Renda; Anna Borrelli; Cristina Pastorino; Daniela Guidone; Arianna Venturini; Alessandro Giraudo; Sine Mandrup Bertozzi; Ilaria Musante; Fabio Bertozzi; Tiziano Bandiera; Federico Zara; Luis J V Galietta; Nicoletta Pedemonte
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

Review 8.  Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series.

Authors:  Christina M Mingora; Patrick A Flume
Journal:  Chest       Date:  2021-06-17       Impact factor: 10.262

Review 9.  Abnormal unsaturated fatty acid metabolism in cystic fibrosis: biochemical mechanisms and clinical implications.

Authors:  Adam C Seegmiller
Journal:  Int J Mol Sci       Date:  2014-09-11       Impact factor: 5.923

10.  From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations.

Authors:  Gudio Veit; Radu G Avramescu; Annette N Chiang; Scott A Houck; Zhiwei Cai; Kathryn W Peters; Jeong S Hong; Harvey B Pollard; William B Guggino; William E Balch; William R Skach; Garry R Cutting; Raymond A Frizzell; David N Sheppard; Douglas M Cyr; Eric J Sorscher; Jeffrey L Brodsky; Gergely L Lukacs
Journal:  Mol Biol Cell       Date:  2016-02-01       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.